Edesa Biotech, Inc.
EDSANasdaqCIK 1540159HealthcareFiscal year ends Sep 30
Latest reported revenue, Q4 FY2021$0Revenue, Q4 FY2021, three months to 2021-09-30$0. XBRL concept
us-gaap:Revenues. 10-K filed 2021-12-28, accession 0001654954-21-013551. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Sep 30, 2021, from the 10-K filed Dec 28, 2021.Latest quarter: Q3 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
- Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q4 FY20242024-09-30 | Q1 FY20252024-12-31 | Q2 FY20252025-03-31 | Q3 FY20252025-06-30 | Q4 FY20252025-09-30 | Q1 FY20262025-12-31 | Q2 FY20262026-03-31 | Q3 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-09-30 | FY20222022-09-30 | FY20232023-09-30 | FY20242024-09-30 | FY20252025-09-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 0.0Revenue, FY2021, twelve months to 2021-09-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2021-12-28, accession 0001654954-21-013551.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue of zero not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue of zero not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (1.10)Diluted EPS, FY2021, twelve months to 2021-09-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2021-12-28, accession 0001654954-21-013551.Report this figure | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | |
| Free cash flow | $m | (13.7)Free cash flow, FY2021, twelve months to 2021-09-30. operating cash flow − capital expenditureOperating cash flow: −$13.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2022-12-16, accession 0001654954-22-016633.Capital expenditure: $6.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2022-12-16, accession 0001654954-22-016633.Report this figure | (12.3)Free cash flow, FY2022, twelve months to 2022-09-30. operating cash flow − capital expenditureOperating cash flow: −$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-12-15, accession 0001654954-23-015632.Capital expenditure: $5.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-12-15, accession 0001654954-23-015632.Report this figure | (6.6)Free cash flow, FY2023, twelve months to 2023-09-30. operating cash flow − capital expenditureOperating cash flow: −$6.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-12-13, accession 0001171843-24-006946.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-12-15, accession 0001654954-23-015632.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 2026-06-30 | $6.7m | 827,500 | Unchanged | |
| Rubric Capital Management LP | 2026-06-30 | $5.4m | 669,500 | Reduced−18,000 | |
| PERCEPTIVE ADVISORS LLC | 2026-06-30 | $4.6m | 563,239 | Unchanged | |
| MILLENNIUM MANAGEMENT LLC | 2026-06-30 | $4.6m | 561,751 | New+561,751 | |
| Stonepine Capital Management, LLC | 2026-06-30 | $3.2m | 456,439 | Added+426,439 | |
| Boxer Capital Management, LLC | 2026-06-30 | $1.7m | 205,000 | New+205,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $665.4k | 81,839 | Reduced−4,127 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $657.6k | 80,879 | Added+3,825 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $589.1k | 72,465 | Reduced−43,256 | |
| VANGUARD FIDUCIARY TRUST CO | 2026-06-30 | $314.8k | 38,718 | Added+272 |
Recent filings
All 748 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2317:24 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001171843-26-006794 |
| 2026-10-1509:15 ET | 8-K | 8.01 Other events | 0001171843-26-006647 |
| 2026-08-2518:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001171843-26-005738 |
| 2026-08-2516:38 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-26-002310 |
| 2026-08-2016:15 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-005686 |
| 2026-08-1316:40 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001171843-26-005502 |
| 2026-08-1316:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005499 |
| 2026-06-1617:06 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001171843-26-004153 |
| 2026-06-1109:20 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-004053 |
| 2026-06-0509:25 ET | 8-K | 8.01 Other events | 0001171843-26-003931 |
Latest annual report
Form 10-K for the fiscal year ended Sep 30, 2025Filed Dec 12, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1540159
- Tickers
- EDSA
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Sep 30
- Incorporated in
- A1
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- Stellar Biotechnologies, Inc. (to 2019-05-30)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:02 ET. Listed shows no prices and gives no investment advice.